Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.
about
The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinomaHigh EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy.Coexpression of periostin and EGFR in patients with esophageal squamous cell carcinoma and their prognostic significanceAnti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.Targeting the epidermal growth factor receptor in solid tumors: focus on safety.Investigational therapies targeting the ErbB family in oesophagogastric cancer.From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.Targeted therapy in esophageal cancer.Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repairOverall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: a phase I study.Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.
P2860
Q27853223-ABBA6E3A-22B1-40EA-AC88-A1D855C1BDBFQ35948006-BADC414B-B843-4BCB-8D19-4DC3A8F93C75Q36210986-75C4EEE8-4399-4764-B585-72AE2F07FC98Q36425414-074C176D-4F6B-47A3-B59D-22DEE66D8B33Q37197513-5C1E1F2D-569E-479B-99E2-90DCDCDED333Q37558860-15AB1789-8FE8-4E3D-BC1B-ACBEDB8ED6E3Q37618803-0F964E28-74A7-4B93-ABF0-A037F86E8A22Q38200654-76EBBBCB-75B3-4DEF-A749-A54EC75417B9Q38221886-DAD63960-24D1-4BE4-97CA-0A5EA8B2946DQ38234000-E5C9BC36-94E5-45D4-834D-BAAA5E3011CAQ38741042-59AB5303-42BA-41D4-8657-BCEF12E628AAQ39802972-FEDC3E4A-528C-4AA6-9F2F-B4B474FDEAB7Q48310631-CB7B0B0C-100E-4AD9-BDD8-665420FA34C4Q49503130-B28E5C1E-DB74-4C9B-A7B2-E1EBE7EE931DQ55002224-ECD5BD36-B1AC-4153-909F-4C6BA1C00BAB
P2860
Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Nimotuzumab combined with radi ...... of a Phase II clinical trial.
@en
Nimotuzumab combined with radi ...... of a Phase II clinical trial.
@nl
type
label
Nimotuzumab combined with radi ...... of a Phase II clinical trial.
@en
Nimotuzumab combined with radi ...... of a Phase II clinical trial.
@nl
prefLabel
Nimotuzumab combined with radi ...... of a Phase II clinical trial.
@en
Nimotuzumab combined with radi ...... of a Phase II clinical trial.
@nl
P2093
P2860
P356
P1476
Nimotuzumab combined with radi ...... of a Phase II clinical trial.
@en
P2093
Dongfu Chen
Junqi Zheng
Luhua Wang
Lujun Zhao
P2860
P304
P356
10.2147/OTT.S50945
P407
P577
2013-11-06T00:00:00Z